JP2013523717A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013523717A5 JP2013523717A5 JP2013502022A JP2013502022A JP2013523717A5 JP 2013523717 A5 JP2013523717 A5 JP 2013523717A5 JP 2013502022 A JP2013502022 A JP 2013502022A JP 2013502022 A JP2013502022 A JP 2013502022A JP 2013523717 A5 JP2013523717 A5 JP 2013523717A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- antibody
- preparation
- tautomer
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000009472 formulation Methods 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 4
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims 4
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 claims 3
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 claims 3
- 229950006790 adenosine phosphate Drugs 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- RQFCJASXJCIDSX-UHFFFAOYSA-N 14C-Guanosin-5'-monophosphat Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(O)=O)C(O)C1O RQFCJASXJCIDSX-UHFFFAOYSA-N 0.000 claims 2
- 229930024421 Adenine Natural products 0.000 claims 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims 2
- 229930010555 Inosine Natural products 0.000 claims 2
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims 2
- 241000725643 Respiratory syncytial virus Species 0.000 claims 2
- 229960000643 adenine Drugs 0.000 claims 2
- 229960000397 bevacizumab Drugs 0.000 claims 2
- 229940104302 cytosine Drugs 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- -1 ethanoadenine Chemical compound 0.000 claims 2
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 claims 2
- 229960003786 inosine Drugs 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- FKCRAVPPBFWEJD-UHFFFAOYSA-N orotidine Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1C(O)=O FKCRAVPPBFWEJD-UHFFFAOYSA-N 0.000 claims 2
- FKCRAVPPBFWEJD-XVFCMESISA-N orotidine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1C(O)=O FKCRAVPPBFWEJD-XVFCMESISA-N 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 229940113082 thymine Drugs 0.000 claims 2
- 229940035893 uracil Drugs 0.000 claims 2
- 229940075420 xanthine Drugs 0.000 claims 2
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 claims 1
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 claims 1
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000023555 blood coagulation Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000001177 diphosphate Substances 0.000 claims 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims 1
- 235000011180 diphosphates Nutrition 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
- 239000001226 triphosphate Substances 0.000 claims 1
- 235000011178 triphosphate Nutrition 0.000 claims 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31931010P | 2010-03-31 | 2010-03-31 | |
| US61/319,310 | 2010-03-31 | ||
| PCT/IB2011/051372 WO2011121559A2 (en) | 2010-03-31 | 2011-03-31 | Stabilized antibody preparations and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013523717A JP2013523717A (ja) | 2013-06-17 |
| JP2013523717A5 true JP2013523717A5 (enExample) | 2014-04-24 |
Family
ID=44022060
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013502022A Pending JP2013523717A (ja) | 2010-03-31 | 2011-03-31 | 安定化された抗体調製物およびその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20130017197A1 (enExample) |
| EP (1) | EP2552411A2 (enExample) |
| JP (1) | JP2013523717A (enExample) |
| CA (1) | CA2794628A1 (enExample) |
| WO (1) | WO2011121559A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9155745B2 (en) | 2009-06-16 | 2015-10-13 | Universite De Geneve | Bevacizumab formulations with lower aggregation propensity, comprising corticosteroid anti-inflammatory drugs |
| JP2013528570A (ja) * | 2010-03-31 | 2013-07-11 | ユニベルシテ ドゥ ジュネーブ | 安定化された抗体調製物およびその使用 |
| US10894083B2 (en) | 2015-01-28 | 2021-01-19 | Pfizer Inc. | Stable aqueous anti-vascular endothelial growth factor (VEGF) antibody formulation |
| CA3151375A1 (en) * | 2019-08-01 | 2021-02-04 | Kushal Garima | Ophthalmic composition of bevacizumab |
| WO2021183814A1 (en) * | 2020-03-11 | 2021-09-16 | University Of Virginia Patent Foundation | Metabolites released from apoptotic cells act as novel tissue messengers |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3064888D1 (en) | 1979-04-30 | 1983-10-27 | Hoechst Ag | Aqueous solutions of proteins stable against denaturization, process for their manufacture, and their utilization |
| US4362661A (en) * | 1979-08-09 | 1982-12-07 | Teijin Limited | Immunoglobulin composition having a high monomer content, and process for production thereof |
| AU3722984A (en) | 1984-01-05 | 1985-07-11 | Manlab Pty. Ltd. | Reagents for immunoassay at elevated temperatures |
| US4808705A (en) * | 1986-12-19 | 1989-02-28 | Cetus Corporation | Stable formulations of ricin toxin a chain and of RTA-immunoconjugates and stabilizer screening methods therefor |
| US6686171B2 (en) * | 1999-05-10 | 2004-02-03 | Tropix, Inc. | Competitive chemiluminescent assay for cyclic nucleotide monophosphates |
| AU2003219664A1 (en) * | 2002-01-16 | 2003-09-02 | Eliezer Rapaport | Methods and therapeutic compositions in the treatment of advanced cancer |
| EP1532983A1 (en) | 2003-11-18 | 2005-05-25 | ZLB Bioplasma AG | Immunoglobulin preparations having increased stability |
| WO2010132047A1 (en) * | 2009-05-14 | 2010-11-18 | Rensselaer Polytechnic Institute | Guanosine/gmp gels and uses thereof |
| JP2013528570A (ja) * | 2010-03-31 | 2013-07-11 | ユニベルシテ ドゥ ジュネーブ | 安定化された抗体調製物およびその使用 |
-
2011
- 2011-03-31 WO PCT/IB2011/051372 patent/WO2011121559A2/en not_active Ceased
- 2011-03-31 US US13/637,041 patent/US20130017197A1/en not_active Abandoned
- 2011-03-31 CA CA2794628A patent/CA2794628A1/en not_active Abandoned
- 2011-03-31 EP EP11715753A patent/EP2552411A2/en not_active Withdrawn
- 2011-03-31 JP JP2013502022A patent/JP2013523717A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7158428B2 (ja) | リボシドの調製のための方法 | |
| ES2989617T3 (es) | Moduladores de receptores de quimioquinas y usos de los mismos | |
| JP4294870B2 (ja) | Ｂ型肝炎の治療のためのβ−Ｌ−２’−デオキシ−ヌクレオシド | |
| ES2927955T3 (es) | Composiciones de nucleótidos y nucleósidos y sus usos | |
| JP2021517132A (ja) | ４’−ハロゲン含有ヌクレオチドおよびヌクレオシド治療組成物ならびにそれらに関連する使用 | |
| KR100270806B1 (ko) | 5-플루오로-2`-데옥시-3`-티아시티딘을 함유하는 b형 간염 치료를 위한 약제 | |
| CA2972014A1 (en) | Fused pyrimidine compounds for the treatment of hiv | |
| WO2014124430A1 (en) | Nucleotide and nucleoside therapeutic compositions and uses related thereto | |
| JP2014521688A5 (enExample) | ||
| CA3214726A1 (en) | Nucleosides and nucleotides analogs as antiviral agents | |
| JP2018500334A (ja) | Ｂ型肝炎ウイルスの治療のためのホスホルアミデート | |
| JP2014518882A5 (enExample) | ||
| JP2013523717A5 (enExample) | ||
| ES2902390T3 (es) | Derivados de imidazol condensados sustituidos por grupos hidroxi terciarios como inhibidores de PI3K-gamma | |
| CN102480957A (zh) | 治疗癌症及非肿瘤病症的方法 | |
| CN109563081A (zh) | 可用作蛋白调节剂的杂环酰胺类 | |
| JP2017537949A5 (enExample) | ||
| JP2010510301A (ja) | 化合物 | |
| JP2006524711A5 (enExample) | ||
| JP2018513832A (ja) | ４’−チオヌクレオシドの新規な化合物、並びにその調製方法、その医薬組成物及びその用途 | |
| RS66554B1 (sr) | Nukleotid hemi-sulfat so za lečenje virusa hepatitisa c | |
| CN114867351B (zh) | 含4′-卤素的核苷酸和核苷治疗组合物以及其相关用途 | |
| JP2013518036A5 (enExample) | ||
| JP2013528570A5 (enExample) | ||
| JP2014510147A5 (enExample) |